Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
Chimeric antigen receptors and methods for reducing toxicity
US11701405B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11701405-B2 |
| Application number | US-201916964471-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 25, 2019 |
| Priority date | Jan 26, 2018 |
| Publication date | Jul 18, 2023 |
| Grant date | Jul 18, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Nucleic acid molecules that include a nucleotide sequence encoding a chimeric antigen receptor (CAR) and a nucleotide sequence encoding a protease sensitive scFv, wherein the chimeric antigen receptor comprises: an scFv targeting a tumor antigen, a spacer, a transmembrane domain, a co-stimulatory domain, and a CD3ζ signaling domain; and the protease-sensitive scFv and the scFv target the same tumor antigen are described.
First claim
Opening claim text (preview).
What is claimed is: 1. A nucleic acid molecule comprising: (a) a nucleotide sequence encoding a chimeric antigen receptor (CAR) comprising amino acids 23 to 665 of SEQ ID NO: 31 and (b) a nucleotide sequence encoding a protease sensitive scFv comprising, from amino to carboxy terminus, a VH domain comprising SEQ ID NO: 33 and a VL domain SEQ ID NO:34 joined by a protease-sensitive linker that is sensitive to MMP-2 or MMP-9. 2. An expression vector comprising the nucleic acid molecule of claim 1 . 3. A viral vector comprising the nucleic acid molecule of claim 1 . 4. A population of human T cells transduced by a vector comprising the nucleic acid molecule of claim 1 . 5. A method of treating cancer in a patient comprising administering a population of autologous or allogeneic human T cells transduced by a vector comprising the nucleic acid molecule of claim 1 . 6. The method of claim 5 , wherein MMP-2 or MMP-9 is present in the tumor microenvironment. 7. The nucleic acid molecule of claim 1 , wherein the protease sensitive scFv comprises the amino acid sequence of SEQ ID NO: 38 or SEQ ID NO: 39.
Assignees
Inventors
Classifications
Matrix metalloproteinases [MMP] · CPC title
CD44 not IgG · CPC title
CD19 or B4 · CPC title
Chimeric antigen receptors [CAR] · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11701405B2 cover?
- Nucleic acid molecules that include a nucleotide sequence encoding a chimeric antigen receptor (CAR) and a nucleotide sequence encoding a protease sensitive scFv, wherein the chimeric antigen receptor comprises: an scFv targeting a tumor antigen, a spacer, a transmembrane domain, a co-stimulatory domain, and a CD3ζ signaling domain; and the protease-sensitive scFv and the scFv target the same t…
- Who is the assignee on this patent?
- Hope City
- What technology area does this patent fall under?
- Primary CPC classification A61K38/177. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).